Category Press Releases

Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech

Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company…

Read MoreJohnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for…

Read MoreSanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting…

Read MoreGilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas  Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the…

Read MoreTakeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas

R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity

R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge,…

Read MoreR&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced…

Read MoreMerck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of…

Read MoreNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for authorizing medicinal products in France, has granted “accès compassionnel” (compassionate access) to AMX0035…

Read MoreAmylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

Stevanato Group Announces Voting Results from its Extraordinary General Meeting

Stevanato Group Announces Voting Results from its Extraordinary General Meeting Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution…

Read MoreStevanato Group Announces Voting Results from its Extraordinary General Meeting

Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health

Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health Elligo Health Research®, the largest healthcare-enabling research organization, today announced it is expanding its Study Marketplace platform with Syneos Health, a leading fully integrated biopharmaceutical solutions organization built to accelerate…

Read MoreElligo Health Research Announces Expansion of Study Marketplace With Syneos Health

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co.…

Read MoreLokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to…

Read MoreBridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments